Navigation Links
Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
Date:10/20/2010

AUSTIN, Texas, Oct. 20 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the third quarter of 2010 on Thursday, November 4, 2010. A press release announcing the results is scheduled for release after the close of trading.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2010, on November 4, 2010, at 5:00 p.m. Eastern time.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts. If you use this software, press and hold the CTRL key when you click on the Register button. Please contact your IT group if you are unable to override this feature. Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP(R) multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.Luminex Corporate Contact:Harriss T. CurrieVice President, Finance and Chief Financial Officer512-219-8020Luminex Investor Relations Contact:Matthew D. ScaloSr. Director of Investor Relations512-219-8020mscalo@luminexcorp.com
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
2. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
3. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
4. Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe
5. Luminex Corporation to Present at UBS Global Life Sciences Conference
6. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
7. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
8. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
9. Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd
10. Physicians Pharmaceutical Corporation Offers Innovative On-Site Drug Dispensaries
11. Arable Corporation Announces New Technology for Clinical Trial Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... LONDON , May 23, 2016 ... Surgical Devices, Diagnostics and Monitoring, and Vision Care ... Market? Which areas are going to grow at the ... potential revenues to 2026, assessing data, trends, opportunities and ... tables, charts, and graphs. Discover the most lucrative areas ...
(Date:5/23/2016)... -- Non-invasive diagnostic test realizes the potential ... to be presented at Yissum’s booth, at IATI-BIOMED 2016 ... of the Hebrew University of Jerusalem announced today ... Ventures MKI, the technology investment arm of Morris Kahn ... for early detection of multiple diseases by analyzing circulating ...
(Date:5/23/2016)... -- Gamida Cell, a leader in cellular ... orphan genetic diseases, announced today it has been awarded ... Israel Innovation Authority (formerly the Office of the Chief ... The mission of the Israel Innovation Authority is to ... and technology, while stimulating economic growth. The ...
Breaking Medicine Technology:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... builder, has announced that it will join America's leading engineers at the American ... held at the Georgia World Congress Center. , Engineers, speakers and exhibitors ...
(Date:5/24/2016)... ... May 24, 2016 , ... BTC ... care blockchain event, Distributed: Health, to be held in Nashville, Tennessee on September ... , A 24-hour Hackathon preceding the event will host teams from around the ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... corporate identity and website at its “Transforming Outcomes” User Conference in Las Vegas ... reflect i2i’s ongoing success to set the market standard for meaningful population health ...
(Date:5/24/2016)... ... May 24, 2016 , ... Local engineering firm, Timmons ... Medical Center located in Woodbridge, VA. The project includes a brand new ... site. , The new 2 story building houses the Central Sterile department, Sterile ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 ... members of its Advisory Board. Joining the Grow Healthy Advisory ... three of them embody the mission of our organization and bring ... to have them as we continue to expand our footprint as ...
Breaking Medicine News(10 mins):